A5019558744- Lymphoma Diagnosis and Treatment
- CAR-T cell therapy research
- Venous Thromboembolism Diagnosis and Management
- CNS Lymphoma Diagnosis and Treatment
- Chronic Lymphocytic Leukemia Research
- Cutaneous lymphoproliferative disorders research
- Viral-associated cancers and disorders
- Atrial Fibrillation Management and Outcomes
- Hemoglobinopathies and Related Disorders
- T-cell and Retrovirus Studies
- Acute Lymphoblastic Leukemia research
- Myeloproliferative Neoplasms: Diagnosis and Treatment
- Chronic Myeloid Leukemia Treatments
- Platelet Disorders and Treatments
- Acute Myeloid Leukemia Research
- Erythropoietin and Anemia Treatment
- Diagnosis and Treatment of Venous Diseases
- Hematological disorders and diagnostics
- Cardiac tumors and thrombi
- Vascular Tumors and Angiosarcomas
- Multiple Myeloma Research and Treatments
- Diverse Scientific Research Studies
- Palliative Care and End-of-Life Issues
- Patient Dignity and Privacy
- Esophageal Cancer Research and Treatment
Thammasat University
2014-2024
Technical University of Munich
2019
University of California, Los Angeles
2002
Event free survival at 24 months (EFS24) has been described as a powerful predictor for outcome in several subtypes of B cell lymphoma. However, it was limitedly T We explored the implication EFS24 marker peripheral lymphoma (PTCL). reviewed 293 systemic PTCL patients 13 nationwide major university hospitals Thailand from 2007 to 2014. The median event (EFS) and overall (OS) our cohort 16.3 27.7 with corresponding 2-year EFS OS 45.8% 51.9%, respectively. A total 118 achieved (no events...
Abstract Background MYC/BCL2 double expression (DE) is associated with poor prognosis in patients diffuse large B-cell lymphoma (DLBCL) receiving rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisolone (R-CHOP). This study aimed to determine whether the addition of DE National Comprehensive Cancer Network Internal Prognostic Index (NCCN-IPI) could improve prediction disease progression DLBCL treated R-CHOP. Methods confirmatory prognostic factor retrospectively recruited...
Objective The Thai Medical School Palliative Care Network conducted this study to establish the current state of palliative care education in medical schools. Methods A questionnaire survey was given 2 groups that included final year students and instructors 16 covered 4 areas related education. Results An insufficient proportion (defined as fewer than 60%) learned nonpain symptoms control (50.0%), goal setting planning (39.0%), teamwork (38.7%), pain management (32.7%). Both reflected...
Background Diffuse large B-cell lymphoma (DLBCL) is the most common aggressive lymphoma. The standard first-line therapy for DLBCL consists of rituximab cyclophosphamide doxorubicin vincristine and prednisone (R-CHOP). About 50–70% patients may be cured by R-CHOP. There was no data on external validation comparison international prognostic index, revised-IPI (R-IPI), enhanced-IPI (NCCN-IPI) to predict treatment outcomes in middle-income country with a resourced-limited setting.Objectives We...
Acute myeloid leukemia (AML) is a common, challenging hematologic malignancy worldwide. Thai data on its characteristics and outcomes have never been systematically reported, to our knowledge. The objective of this study was determine the clinical features patients with AML.This prospective observational nine academic hospitals. Patients newly diagnosed AML were invited register online.A total 679 included. presence circulating peripheral blood blasts correlated high white cell count....
A 68-year-old woman was admitted to the hospital for elective total knee arthroplasty in both knees without preceding heparin exposure. She developed adrenal haemorrhage and thrombocytopaenia on postoperative day 12, followed by right leg arterial occlusion multiple venous intra-abdominal sites thrombosis. After given unfractionated treat occlusion, platelet count gradually declined. Spontaneous heparin-induced diagnosed activation test with light transmission aggregometry. The patient...
Background: Peripheral T cell lymphoma (PTCL) is relatively uncommon compared to B lymphoma, however, it generally carries worse prognosis. Treatment failure and early relapse are major dilemma of PTCL. Identification high-risk patients using various tools may better refine long-term prognosis PTCL patients. There were data indicating event free survival (EFS) at 12 months (EFS12) 24 (EFS24) as strong surrogate predictors for disease-related outcomes in many B-cell lymphoma. However, the...
Event-free survival at 12 months (EFS12) is a surrogate endpoint for long-term outcomes in many histologic lymphoma subtypes. However, most reports have primarily investigated the implication of EFS12 advanced-stage non-Hodgkin (NHL). There are limited data regarding significance early-stage NHL. Herein, we evaluated prognostic patients with stage 1 diffuse large B-cell (DLBCL). Out 282 DLBCL who received intensive therapy, 227 (80.5%) achieved EFS12. The 4-year overall (OS) was 91.4% and...